Ranolazine is an anti-anginal indicated for the treatment of chronic angina. It is available as extended-release tablets and granules for oral use. MedsAcross supplies Ranolazine for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
ASPRUZYO Sprinkle is indicated for the treatment of chronic angina. ASPRUZYO Sprinkle may be used with beta-blockers, nitrates, calcium channel blockers, anti‑platelet therapy, lipid-lowering therapy, ACE inhibitors, and angiotensin receptor blockers. ASPRUZYO Sprinkle is an antianginal indicated for the treatment of chronic angina.
Source: US FDA prescribing information
The mechanism of action of ranolazine's antianginal effects has not been determined. Ranolazine has anti-ischemic and antianginal effects that do not depend upon reductions in heart rate or blood pressure. It does not affect the rate-pressure product, a measure of myocardial work, at maximal exercise. Ranolazine at therapeutic levels can inhibit the cardiac late sodium current (I Na ). However, the relationship of this inhibition to angina symptoms is uncertain. The QT prolongation effect of ranolazine on the surface electrocardiogram is the result of inhibition of I Kr which prolongs the ventricular action potential.
Source: US FDA prescribing information
500 mg orally twice daily and increase to 1000 mg orally twice daily, based on clinical symptoms Dosing Information Initiate ASPRUZYO Sprinkle dosing at 500 mg orally twice daily and increase to 1000 mg orally twice daily, as needed, based on clinical symptoms. The maximum recommended daily dose of ASPRUZYO Sprinkle is 1000 mg twice daily. If a dose of ASPRUZYO Sprinkle is missed, take the prescribed dose at the next scheduled time, do not double the next dose. Directions for use with soft food (e.g., applesauce and yogurt) Sprinkle granules on one tablespoonful of soft food and consume immediately. Do not crush or chew the granules. Direction for nasogastric and gastric tube administration Nasogastric (NG) tube: Add the content of a sachet to a plastic catheter tip syringe and add 50 mL of water. Gently shake the syringe for approximately 15 seconds.
Source: US FDA prescribing information
ASPRUZYO Sprinkle is contraindicated in patients: Taking strong inhibitors of CYP3A Taking inducers of CYP3A With liver cirrhosis Strong CYP3A inhibitors (e.g., ketoconazole, clarithromycin, nelfinavir). CYP3A inducers (e.g., rifampin, phenobarbital, St. John's wort). Liver cirrhosis
Source: US FDA prescribing information
QT interval prolongation: Can occur with ranolazine. Little information available on high doses, long exposure, use with QT interval‑ prolonging drugs, potassium channel variants causing prolonged QT interval, in patients with a family history of (or congenital) long QT syndrome, or in patients with known acquired QT interval prolongation. Renal failure: Monitor renal function after initiation and periodically in patients with moderate to severe renal impairment (CrCL <60 mL/min). If acute renal failure develops, discontinue ASPRUZYO Sprinkle.
Source: US FDA prescribing information
Most common adverse reactions (> 4% and more common than with placebo) are dizziness, headache, constipation, nausea.
Source: US FDA prescribing information
Moderate CYP3A inhibitors (e.g., diltiazem, verapamil, erythromycin): Limit ASPRUZYO Sprinkle to 500 mg twice daily. P-gp inhibitors (e.g., cyclosporine): Ranolazine exposure increased. Titrate ASPRUZYO Sprinkle based on clinical response. CYP3A substrates: Limit simvastatin to 20 mg when used with ASPRUZYO Sprinkle. Doses of other sensitive CYP3A substrates (e.g., lovastatin) and CYP3A substrates with narrow therapeutic range (e.g., cyclosporine, tacrolimus, sirolimus) may need to be reduced with ASPRUZYO Sprinkle. OCT2 substrates: Limit the dose of metformin to 1700 mg daily when used with ASPRUZYO Sprinkle 1000 mg twice daily. Doses of other OCT2 substrates may require adjusted doses. Drugs transported by P-gp (e.g., digoxin), or drugs metabolized by CYP2D6 (e.g., tricyclic antidepressants) may need reduced doses when used with ASPRUZYO Sprinkle.
Source: US FDA prescribing information
Store ASPRUZYO Sprinkle at 20°C to 25°C (68°F to 77°F), excursions permitted between 15°C to 30°C (59°F to 86°F).
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
3 presentations of Ranolazine, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Ranolazine 500 mg extended-release tabletOralGeneric name | — | US FDA | Available on request |
| Ranolazine 1000 mg extended-release tabletOralGeneric name | — | US FDA | Available on request |
| Aspruzyo Sprinkle 1000 mg granulesOral | Sun Pharmaceutical IndustriesIndia | US FDA | Available on request |
1 brand names across 1 markets.
United States
Indian manufacturers are highlighted.
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
Conditions linked to Ranolazine in public data. This is not a list of approved uses, see the clinical information.
Yes, on request. MedsAcross lists 3 presentations of Ranolazine and sources them for licensed hospitals, importers and physicians against valid import documents. Indian manufacturers include Sun Pharmaceutical Industries.
The catalogue lists 1 brand names for Ranolazine, including Aspruzyo Sprinkle.
Yes. The US FDA first approved Ranolazine on 27 January 2006, according to Drugs@FDA.
Yes. Ranolazine has a central EU marketing authorisation (status: authorised), according to European Medicines Agency data.
No listed presentation of Ranolazine is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Ranolazine is classified under ATC code C01EB18 (Ranolazine).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.